Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xeris Pharmaceuticals Inc (NQ: XERS )

2.905 +0.195 (+7.20%)
Streaming Delayed Price Updated: 1:10 PM EDT, Sep 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Xeris Pharmaceuticals Inc

< Previous 1 2 3 4 Next >
Xeris Ships One Millionth Gvoke® Unit
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Announces First Participant Dosed in a Phase 2 Clinical Study of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) in Patients With Hypothyroidism
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Participate at the Jefferies Healthcare Conference
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Reports First Quarter 2023 Financial Results
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol™ Formulations
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJect™
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Appoints Ricki Fairley to Board of Directors
From Xeris Biopharma Holdings
Via Business Wire
Xeris Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Report Fourth Quarter and Full-Year 2022 Financial Results on March 8, 2023
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Participate in the SVB Securities Global Biopharma Conference 2023
From Xeris Biopharma, Inc.
Via Business Wire
Xeris Biopharma Announces FDA Grants Orphan-drug Exclusivity for Recorlev®
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Present at 41st Annual J.P. Morgan Healthcare Conference
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Updates Its Outlook For 2022
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Announces Plans for a Phase II Dose-Finding Study for Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) as Replacement Therapy for Hypothyroidism
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Announces Research Collaboration and Option Agreement With Horizon Therapeutics plc for XeriJect™ Formulation of Teprotumumab
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Reports Third Quarter 2022 Financial Results and Recent Events
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Report Third Quarter 2022 Financial Results on November 9, 2022
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Announces Results of the Extended Evaluation of Recorlev® (Levoketoconazole) From the Phase 3 Sonics Study Published in the European Journal of Endocrinology
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Announces Positive Topline Phase 1 Clinical Data of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121); Hosts Conference Call and Webcast
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Reports Second Quarter Financial Results and Upcoming Events
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Report Second Quarter 2022 Financial Results on August 10, 2022
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris’ Commercialization Partner for Ogluo®, Tetris Pharma Ltd, to Be Acquired by Arecor Therapeutics
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Announces Full Results From the Logics Study of Recorlev® and Presentation of New Burden of Illness in Cushing’s Syndrome Data at AACE Annual Meeting May 12-14
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Reports First Quarter Financial Results and Upcoming Events
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Report First Quarter 2022 Financial Results on May 11, 2022
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Announces Gvoke® Kit Is Now Available for the Treatment of Severe Hypoglycemia in Adults and Children With Diabetes Ages 2 And Above
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
From Xeris Biopharma Holdings
Via Business Wire
Xeris Biopharma Announces Recorlev® (levoketoconazole) Is Now Commercially Available for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Reaffirms 2021 Guidance and Provides Business Update
From Xeris Biopharma Holdings, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.